GC方案治疗晚期尿路上皮癌近期疗效评价

Study of short-term efficacy of gemcitabine plus cisplatin in treating advanced urothelial carcinoma

目的观察吉西他滨联合顺铂（Gemcitabine＋Cisplatin，GC）方案治疗晚期尿路上皮癌的近期疗效和不良反应。方法21例尿路上皮癌患者均经病理证实，其中膀胱癌17例，输尿管癌3例，肾盂癌1例。化疗前肝肾功能和血常规检测均正常。全身化疗方案：吉西他滨1000mg／m。，静脉滴注30rain，第1、8天各1次；顺铂70mg／m^2，充分水化，静脉滴注30～60min，第1天。21d为一个疗程。每个疗程结束评价疗效及毒副反应。结果完成1个周期11例，2个周期4例，3个周期4例，4个周期2例。近期疗效：完全缓解（CR）0例，部分缓解（PR）10例，稳定（SD）6例，进展（PD）5例，总有效率47．6％。主要不良反应为骨髓抑制和消化道反应，多为轻中度。无治疗相关性死亡病例。结论吉西他滨联合顺铂（GC）方案是治疗晚期尿路上皮癌的有效方法，患者耐受性好。

Objective To determine the efficacy and toxicity of gemcitabine plus cisplatin in treating advanced urothelial carcinoma（ TCC ）. Methods Twenty one patients with advanced or metastatic TCC of urinary tract （ 17 cases of bladder TCC, 3 of ureteral TCC and 1 of renal pelvic TCC） ,who were pathologically confirmed, were treated with gemcitabine 1000 mg/m^2 （iv infusion） on day 1 and day 8 and cisplatin 70 mg/m^2（iv infusion） on day 1 every 21 days. The response rate, liver and renal functions and blood routine test results were evaluated after every cycle. Results Ten patients（47.6% ） had partial response, 6 were stable and 5 patients had progression. The overall response rate was 47.6%. The main toxic effects included myelosuppression, nausea and vomiting, which were mild or moderate and disappeared after treatment. No chemotherapy-associated death occurred. Conclusion Gemcitabine and cisplatin combination therapy is effective in treating advanced urothelial carcinoma, and the toxicity is well tolerated.